共 50 条
- [11] Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA)LANCET HAEMATOLOGY, 2020, 7 (12): : E874 - E883Roussel, MurielleMoreau, PhilippeHebraud, BenjaminLaribi, KamelJaccard, ArnaudDib, MamounSlama, BorhaneDorvaux, VeroniqueRoyer, BrunoFrenzel, LaurentZweegman, SonjaKlein, Saskia K.Broijl, AnnemiekJie, Kon-SiongWang, JianpingVanquickelberghe, VeroniqueBoer, Carla deKampfenkel, TobiasGries, Katharine S.Fastenau, JohnSonneveld, Pieter
- [12] Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantationHEMATOLOGY TRANSFUSION AND CELL THERAPY, 2020, 42 (02) : 118 - 124Crusoe, Edvan De QueirozHigashi, FabianaMartinez, GraciaBittencourt, RosanePinto Neto, Jorge VazSousa, LaisSantucci, RodrigoPessoa Magalhaes, Roberto JoseColli, GilbertoMarques Nunes, Renata FerreiraRibeiro, GlacianoNicacio, JandirZanella, Karla RichterKutner, Jose MauroMagalhaes, AndreLeao, DanielleHallack Neto, Abrahao EliasBraga, WalterSouza, Emanuella G.Guimaraes, Antonio Julio A. M.Durigon, Giovanna SteffenelloLaks, DaniMaiolino, Angelode Moraes Hungria, Vania Tietsche
- [13] A Matching-adjusted Indirect Comparison (MAIC) of Bortezomib-Thalidomide-Dexamethasone (VTd) and Daratumumab Plus VTd (D-VTd) Versus Bortezomib-Cyclophosphamide-Dexamethasone (VCd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) who are Transplant Eligible (TE)CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E201 - E202Sonneveld, PieterDejoie, ThomasZweegman, SonjaMerz, MaximilianWeisel, KatjaLam, AnnetteKrotneva, StanimiraProskorovsky, IrinaKampfenkel, Tobiasde Boer, CarlaCote, SarahMoreau, Philippe
- [14] Clinical outcomes of transplant-eligible multiple myeloma patients treated with frontline thalidomide/dexamethasoneBONE MARROW TRANSPLANTATION, 2015, 50 : 5626 - 5627Ha, H.Youk, J.Park, H.Lee, J. -OBang, S. -M.Kim, K-H.Park, J. -H.Koh, Y.Kim, I.Yoon, S. -S.Park, S.
- [15] Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone (D-VTd) in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of High-risk Patients (Pts) in CASSIOPEIACLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E2 - E3Sonneveld, PieterAttal, MichelPerrot, AuroreHulin, CyrilleCaillot, DenisFacon, ThierryLeleu, XavierBelhadj-Merzoug, KarimKarlin, LionelBenboubker, LoftiLevin, Mark-DavidMinnema, MoniqueWesterman, MatthijsDelforge, MichelZweegman, SonjaPei, Lixiade Boer, CarlaVanquickelberghe, VeroniqueKampfenkel, TobiasMoreau, Philippe
- [16] Daratumumab plus bortezomib, thalidomide, and dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM): Baseline SLiM-CRAB based subgroup analysis of CASSIOPEIA.JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Touzeau, CyrilleMoreau, PhilippePerrot, AuroreHulin, CyrilleDib, MamounTiab, MouradCaillot, DenisFacon, ThierryLeleu, Xaviervan de Donk, Niels W. C. J.Broijl, AnnemiekZweegman, SonjaLevin, Mark-DavidDelforge, MichelPei, LixiaVanquickelberghe, VeroniqueDe Boer, CarlaKampfenkel, TobiasVermeulen, JessicaSonneveld, Pieter
- [17] A Comparison of Cyclophosphamide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Transplant Eligible Patients with Newly Diagnosed Multiple MyelomaBLOOD, 2016, 128 (22)Figueiredo, AmarilisAtkins, HaroldMallick, RanjeetaKekre, NatashaKew, AndreaMcCurdy, Arleigh
- [18] Phase 3 randomized study of daratumumab (DARA) plus bortezomib/thalidomide/dexamethasone (D-VTd) vs VTd in transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 1 results.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Moreau, PhilippeAttal, MichelHulin, CyrilleBene, Marie-ChristineBroijl, AnnemiekCaillot, DenisDelforge, MichelDejoie, ThomasFacon, ThierryLambert, JeromeLeleu, XavierMacro, MargaretPerrot, AuroreZweegman, SonjaAhmadi, TahamtanChiu, ChristopherPei, LixiaVermeulen, JessicaAvet-Loiseau, HerveSonneveld, Pieter
- [19] Response and survival outcomes of daratumumab, lenalidomide, bortezomib and dexamethasone (D-RVD) induction in transplant-eligible newly diagnosed multiple myeloma (NDMM) patientsCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S113 - S113Joseph, NishaKaufman, JonathanLonial, SagarHofmeister, CraigDhodapkar, MadhavGupta, VikasDiCamillo, SaraRoberts, DanielleBoise, LawrenceNooka, Ajay
- [20] Superiority of Triple Combination Bortezomib plus Cyclophosphamide and Dexamethasone (VCD) Versus Thalidomide plus Cyclophosphamide and Dexamethasone (CTD) in Newly Diagnosed Multiple Myeloma Transplant-Eligible PatientsBLOOD, 2017, 130Crusoe, Edvan De QueirozHigashi, FabianaMartinez, GraciaBittencourt, RosaneMaiolino, AngeloSousa, LaisNunes, Renata Ferreira MarquesRibeiro, GlacianoNicacio, JandirZanella, Karla RichterMagalhaes, AndreLeao, DaniellePinto Neto, Jorge VazHallack Neto, Abrahao EliasBraga, WalterSouza, Emmanuella G.Guimaraes, Antonio Julio A. M.Durigon, Giovanna SteffenelloLaks, DaniKutner, Jose MauroColli, GilbertoSantucci, RodrigoMagalhaes, Roberto Jose PessoaHungria, Vania T. M.